ATE510853T1 - Tlr2-antagonistischer antikörper und dessen verwendung - Google Patents

Tlr2-antagonistischer antikörper und dessen verwendung

Info

Publication number
ATE510853T1
ATE510853T1 AT04765554T AT04765554T ATE510853T1 AT E510853 T1 ATE510853 T1 AT E510853T1 AT 04765554 T AT04765554 T AT 04765554T AT 04765554 T AT04765554 T AT 04765554T AT E510853 T1 ATE510853 T1 AT E510853T1
Authority
AT
Austria
Prior art keywords
directed
antibody
prevention
nucleic acid
treatment
Prior art date
Application number
AT04765554T
Other languages
English (en)
Inventor
Carsten Kirschning
Guangxun Meng
Hermann Wagner
Original Assignee
Univ Muenchen Tech
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Muenchen Tech, Amgen Inc filed Critical Univ Muenchen Tech
Application granted granted Critical
Publication of ATE510853T1 publication Critical patent/ATE510853T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04765554T 2003-09-23 2004-09-23 Tlr2-antagonistischer antikörper und dessen verwendung ATE510853T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03021461 2003-09-23
PCT/EP2004/010700 WO2005028509A1 (en) 2003-09-23 2004-09-23 Tlr2 antagonistic antibody and use thereof

Publications (1)

Publication Number Publication Date
ATE510853T1 true ATE510853T1 (de) 2011-06-15

Family

ID=34354423

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04765554T ATE510853T1 (de) 2003-09-23 2004-09-23 Tlr2-antagonistischer antikörper und dessen verwendung

Country Status (4)

Country Link
US (2) US8623353B1 (de)
EP (1) EP1664118B1 (de)
AT (1) ATE510853T1 (de)
WO (1) WO2005028509A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1664118B1 (de) 2003-09-23 2011-05-25 Technische Universität München Tlr2-antagonistischer antikörper und dessen verwendung
US8029794B2 (en) 2004-12-10 2011-10-04 Novimmune S.A. Combining therapies targeting multiple toll-like receptors
US20100143336A1 (en) * 2007-04-26 2010-06-10 Opsona Therapeutics Limited Toll-like receptor binding epitope and compositions for binding thereto
ES2441189T3 (es) 2007-05-14 2014-02-03 Novimmune Sa Polipéptidos de unión al receptor de Fc con funciones efectoras modificadas
AU2008267151B2 (en) 2007-06-28 2014-02-20 Neuramedy Co., Ltd. Composition and method for treatment of autoimmune disease
CA2693237C (en) 2007-08-03 2016-11-01 Opsona Therapeutics Limited Anti-toll-like receptor 2 antibodies for use in the treatment of cardiac inflammatory conditions
IE20090514A1 (en) * 2009-07-06 2011-02-16 Opsona Therapeutics Ltd Humanised antibodies and uses therof
EP2812434B1 (de) * 2012-02-09 2018-03-28 Bavarian Nordic A/S Agonisten und antagonisten des toll-like-rezeptors (tlr) 13
GB201205633D0 (en) 2012-03-30 2012-05-16 Opsona Therapeutics Ltd Toll-like receptor 2 binding epitope and binding members thereto
EP2722342A1 (de) 2012-10-19 2014-04-23 Opsona Therapeutics Limited Verfahren und Zusammensetzungen zur Behandlung von Pankreaskrebs
US10047164B2 (en) 2012-10-19 2018-08-14 Opsona Therapeutics Limited Methods and compositions for the treatment of pancreatic cancer
EP2970496B1 (de) 2013-03-12 2018-07-18 Institute of Arthritis Research LLC Immunologisch aktives polypeptid
CN106062193B (zh) 2014-02-28 2020-08-25 安斯泰来制药株式会社 与人tlr2及人tlr4结合的双特异性抗体
US20170137820A1 (en) * 2014-08-06 2017-05-18 Bavarian Nordic A/S Agonists and antagonists of toll-like receptor (tlr) 13
BR112019000635A2 (pt) * 2015-07-13 2019-04-30 Universite Laval inibidor de receptor 2 do tipo toll (tlr2) e seu uso, anticorpo, composição e método para tratar uma afecção inflamatória
US10196453B2 (en) * 2016-05-20 2019-02-05 University Of Virginia Patent Foundation Compositions and methods for treating Clostridium difficile infection
EP3548081B1 (de) 2016-12-02 2021-11-10 Neuramedy Co., LTD. Verfahren und zusammensetzungen zur behandlung von myelodysplastischem syndrom
EP3583949A1 (de) 2018-06-19 2019-12-25 Opsona Therapeutics Limited Toll-like rezeptor 2 (tlr2) antagonisten zur behandlung von ovarialkrebs
EP3864048A1 (de) 2018-10-11 2021-08-18 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Bakterien, die einzelkettige antikörper gegen toll-ähnliche rezeptoren exprimieren
CN111393530A (zh) * 2020-03-30 2020-07-10 中国人民解放军南部战区总医院 新人源tlr2胞外区段单克隆抗体及其制备方法和应用
CN111440240A (zh) * 2020-03-30 2020-07-24 中国人民解放军南部战区总医院 一种单克隆抗体及其制备方法和应用
US20220257633A1 (en) * 2021-02-17 2022-08-18 The Provost, Fellows, Foundation Scholars, & The O Method of treating age-related macular degeneration

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9927332D0 (en) 1999-11-18 2000-01-12 Leiv Eiriksson Nyfotek As Novel antibody and uses thereof
JP4790937B2 (ja) 2001-07-09 2011-10-12 ティーピーオー ホンコン ホールディング リミテッド 反射電極を形成する方法及び液晶表示装置
WO2003070761A1 (en) * 2002-02-19 2003-08-28 Yeda Research And Development Co. Ltd. Dual-effect ligands comprising anti-inflammatory hsp peptide epitopes for immunomodulation
EP1664118B1 (de) 2003-09-23 2011-05-25 Technische Universität München Tlr2-antagonistischer antikörper und dessen verwendung
US7312320B2 (en) * 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
US8029794B2 (en) * 2004-12-10 2011-10-04 Novimmune S.A. Combining therapies targeting multiple toll-like receptors

Also Published As

Publication number Publication date
US8623353B1 (en) 2014-01-07
WO2005028509A1 (en) 2005-03-31
US9458234B2 (en) 2016-10-04
EP1664118B1 (de) 2011-05-25
EP1664118A1 (de) 2006-06-07
US20140343256A1 (en) 2014-11-20

Similar Documents

Publication Publication Date Title
ATE510853T1 (de) Tlr2-antagonistischer antikörper und dessen verwendung
EA201000424A1 (ru) Антитела к il-23
MX2007001338A (es) Anticuerpos antagonistas de il-17.
NZ594682A (en) Fully human antibodies specific to cadm1
AR075790A2 (es) Anticuerpos anti -ngf humanos neutralizantes como inhibidores selectivos de la via de ngf (factor de crecimiento neural)
UA106607C2 (uk) Білки специфічного зв'язування і їх застосування
CY1117036T1 (el) Ανθρωπινα αντισωματα που προσδενουν cxcr4 και χρησεις αυτων
IL200373A (en) A monoclonal antibody that binds to 3erbb and a pharmacological preparation that includes the same to inhibit 3erbb signaling in humans
NZ600022A (en) Anti CD37 antibodies
NZ603499A (en) Human cytomegalovirus neutralizing antibodies and uses thereof
TW200503721A (en) Aminoquinoline compounds
NZ596295A (en) Anti-5T4 antibodies and uses thereof
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
MX2011000768A (es) Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos.
GEP20104922B (en) Antibodies to m-csf
EP3255063A3 (de) Antikörper gegen matrix-metalloproteinase-9
ATE382053T1 (de) System zur antikörperexpression und- synthese
NZ601271A (en) Cd127 binding proteins
BRPI0409879A (pt) composições e métodos para imunoterapia especìfica wt1
NZ595792A (en) Antibodies specific to cadherin-17
EA201491724A1 (ru) Антитела, нейтрализующие rsv, mpv и pvm, и их применения
ATE504602T1 (de) Für humane matriptase spezifische bindungsproteine
TW200609225A (en) Pyrimidinone compounds
TW200801038A (en) Immunoglobulins
PE20240589A1 (es) ANTICUERPOS CD1a Y SU USO

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties